Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort-Reference-Cited by-同舟云学术

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Published:2016-02 Issue:2 Volume:27 Page:281-286
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mazières J.,Barlesi F.,Filleron T.,Besse B.,Monnet I.,Beau-Faller M.,Peters S.,Dansin E.,Früh M.,Pless M.,Rosell R.,Wislez M.,Fournel P.,Westeel V.,Cappuzzo F.,Cortot A.,Moro-Sibilot D.,Milia J.,Gautschi O.

Funder

CAPTOR academic

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/2/281/6677560/mdv573.pdf

Reference24 articles.

1. Management of non-small-cell lung cancer: recent developments;Reck;Lancet,2013

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

4. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives;Mazieres;J Clin Oncol,2013

5. Neratinib (N) with our without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study;Besse,2014

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-01-27

2. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors;Journal of Clinical Oncology;2024-01-20

3. Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report;Frontiers in Oncology;2024-01-18

4. Research Progress in Clinical Therapeutic Efficacy and Safety of HER2-Positive Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024

5. HER2-Mutant Advanced and/or Metastatic Non–Small Cell Lung Cancer: a US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes;Clinical Lung Cancer;2024-01